Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Indoco Remedies Limited
WARNING LETTER
•Indoco Remedies Limited•July 26, 2024

Indoco Remedies Limited – FDA Warning Letter, Jul 26, 2024

Record Details

The FDA issued a Warning Letter to Indoco Remedies Limited following an inspection from July 16 to 26, 2024, at their Goa, India facility. The inspection revealed significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B). The firm's August 15, 2024 response to the FDA 483 was deemed inadequate. Key violations include failure to record and justify deviations from required laboratory control mechanisms (21 CFR 211.160(a)), particularly concerning microbiological testing reliability. The firm also failed to establish and follow appropriate written procedures to prevent microbiological contamination of sterile drug products, including validation of aseptic processes (21 CFR 211.113(b)), evidenced by inadequate airflow studies. Deficiencies were noted in maintaining equipment for aseptic conditions (21 CFR 211.42(c)(10)(vi)), with unsuitable conditions in ISO 5 areas. Furthermore, the firm failed to thoroughly investigate unexplained discrepancies or batch failures (21 CFR 211.192), with complaint investigations relying on flawed analyses. Finally, an inadequate quality unit was identified, with responsibilities not fully followed, particularly concerning the review of chromatography data software audit trails (21 CFR 211.22(a) and 211.22(d)). These are repeat violations from a 2023 inspection, indicating inadequate executive management oversight and an ineffective quality system. The FDA recommends engaging a qualified CGMP consultant (21 CFR 211.34). The firm must promptly correct all violations, as failure to do so may result in the FDA withholding approval of new applications, re-inspection, and refusal of admission of products into the U.S. A written response detailing corrective actions is required within 15 working days.

Company
Indoco Remedies Limited
Inspection date
July 26, 2024
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · e38cf119-2868-489e-987f-8acda3d4a076

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.160(a)21 CFR 211.113(b)21 CFR 211.42(c)(10)(vi)21 CFR 211.19221 CFR 211.22(a)21 CFR 211.22(d)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Indoco Remedies Limited
  • 483 - 2026-09-04September 4, 2026
  • 483 - 2024-07-26July 26, 2024
  • 483 - 2023-02-28February 28, 2023
  • 483 - 2019-06-04June 4, 2019
  • WARNING_LETTER - 2019-01-25January 25, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Indoco Remedies Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.